<DOC>
	<DOCNO>NCT00418327</DOCNO>
	<brief_summary>The purpose study establish recommend dose/Maximum Tolerated Dose ( MTD ) Tarceva child single agent combination radiation therapy</brief_summary>
	<brief_title>Safety Study Tarceva Children With Refractory Relapsed Malignant Brain Tumors Newly Diagnosed Brain Stem Glioma</brief_title>
	<detailed_description>Prognosis relapse malignant brain tumor poor . Those brain stem gliomas dismal ; median survival child exceed 9 month . Radiation therapy may result early transient amelioration symptom , contribute increase prolong survival . Moreover , chemotherapy increase outcome date.Prados et al . report encouraging result phase I study TarcevaTM/OSI-774 alone temozolomide ( TMZ ) patient malignant glioma . Of 25 evaluated patient , 6 experience PR : 4 GBM ( glioblastoma multiforme ) 1 grade 3 astrocytoma treat TarcevaTM alone , 1 GBM treat TarcevaTM/TMZ ; 2 minor response , 3 stable disease . These result malignant glioma lack efficacy brain stem glioma current treatment suggest evaluation new therapeutic agent child relapse brain tumor upfront diagnosis brain stem glioma combination radiation therapy .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm malignant brain tumor Disease must consider refractory first line relapse conventional therapy effective conventional treatment exists.· Newly diagnose , histologically proven brain stem glioma , except pilocytic astrocytomas . Age : 1 ≤ 21 year age study entry Life expectancy : least 8 week ECOG Performance status ≤ 1 LanskyPlay Scale &gt; = 70 % , include child motor paresis due disease Measurable evaluable disease No serious concomitant illness No organ toxicity &gt; grade 2 NCICTC AE v3.0 , except alopecia neurological symptom due disease Patients spontaneous intratumoral hemorrhage include study , exception small postbiopsy hemorrhage due biopsy procedure Pregnant breast feed woman Uncontrolled intercurrent illness active infection Chemotherapy within 4 week prior study medication ( within 6 week , regimen contain nitrosourea ) Radiation therapy within 6 week prior study medication Any clinical nonclinical evidence pulmonary dysfunction preexist lung disease Severe cardiac pathology ; history myocardial infarction within year prior inclusion Any significant ophthalmologic abnormality , especially severe dry eye syndrome , keratoconjunctivitis sicca , Sjögren syndrome , severe exposure keratitis disorder likely increase risk corneal epithelial lesion Treatment Coumarin ( warfarin )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>refractory relapse malignant brain tumor</keyword>
	<keyword>newly diagnose brain stem glioma</keyword>
</DOC>